(Q40762705)

23 September 2017

Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment (English)

1 reference

23 September 2017

Jeandidier N

1

1 reference

PubMed ID

10837697

23 September 2017

Boivin S

series ordinal

2

1 reference

PubMed ID

10837697

23 September 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

Advanced Drug Delivery Reviews

23 September 2017

1 reference

23 September 2017

35

1 reference

23 September 2017

2-3

1 reference

23 September 2017

179-198

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Excess costs of medical care for patients with diabetes in a managed care population

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

The cost to health plans of poor glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intensive insulin therapy in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Future developments in insulin delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Influence of insulin pen injection frequency on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

NPH insulin administration by means of a pen injector.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Influence of intensified insulin regimen on quality of life and metabolic control in insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Use of the pen delivery system for intensive insulin therapy in college-age students with type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin pens in elderly diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effect of patient-selected intensive insulin therapy on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Evaluation of the insulin jet injector as a potential source of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Jet-injected insulin is associated with decreased antibody production and postprandial glucose variability when compared with needle-injected insulin in gestational diabetic women.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Painfulness of needle and jet injection in children with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Risks of jet injection of insulin in children

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

The Medi-Jector II: efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Human insulin-induced lipoatrophy. Successful treatment using a jet-injection device

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alteration of the risk factor paradigm for discontinuance of insulin pump therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Severe autonomic neuropathy treated with subcutaneous insulin infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Remission of severe hypoglycemic incidents in young diabetic children treated with subcutaneous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Severe lipoatrophy with human insulin: successfully treated by CSII

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Severe or life-threatening hypoglycemia in insulin pump treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Quality control in patient self-monitoring of blood glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Are presently available insulin analogues clinically beneficial?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin-like growth factor I therapy for diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Does C-peptide have a physiological role?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

C-peptide revisited--new physiological effects and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

The kinetics of peritoneal insulin absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CSII)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Chemical stability of insulin in a delivery system environment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Clinical trial of programmable implantable insulin pump for type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabète du Traitement par Implants Actifs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Evadiac Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Normalization of Composition of Triglyceride-Rich Lipoprotein Subfractions in Diabetic Subjects During Insulin Infusion With Programmable Implantable Medication System

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin delivery decreases the levels of chylomicron remnants in patients with IDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Intraperitoneal insulin administration does not modify plasminogen activator inhibitor 1 levels in IDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

SHBG (sex hormone binding globulin) levels in insulin dependent diabetic patients according to the route of insulin administration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors, and obstructing materials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Pathogenesis and prevention of adhesion formation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Immunogenicity and allergenic potential of animal and human insulins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Five cases of hyperthyroidism in type I diabetic patients treated with intraperitoneal insulin infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Pressure dermatitis from an implanted pacemaker.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Noninvasive blood glucose monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Non-invasive glucose monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Advances and prospects in glucose assay technology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Artificial pancreas, glucose sensors and the impact upon diabetology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Combination of microdialysis and glucose sensor for continuous on line measurement of the subcutaneous glucose concentration: theory and practical application

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Dermal interstitial glucose as an indicator of ambient glycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Implantation of non-toxic materials from glucose sensors: evidence for specific antibodies detected by ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Alternative insulin delivery systems: how demanding should the patient be?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Algorithms for adjustment of insulin dosage by patients who monitor blood glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Insulin dosage adjustment using manual methods and computer algorithms: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Application of computers in diabetes care--a review. II. Computers for decision support and education

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

Artificial endocrine pancreas and optimal blood glucose regulation in diabetic patients--from bedside-type to wearable-type

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900072-6

7 January 2021

10.1016/S0169-409X(98)00072-6

Identifiers

DOI

1 reference

23 September 2017

1 reference

PubMed ID

10837697